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The commonplace description of phase 1 clinical trials in oncology as
“primarily concerned with safety” is belied by their near universal adop-
tion of dose-escalation practices which are inherently unsafe. In con-
trast with dose titration, cohort-wise dose escalation regards patients as
exchangeable, an indefensible assumption in the face of widely appreci-
ated inter-individual heterogeneity in pharmacokinetics and pharmacody-
namics (PKPD). I have previously advanced this argument in terms of a
precautionary coherence principle that brings the well-known coherence
notion of Cheung (2005) into contact with modern imperatives of patient-
centeredness and precision dosing. Here, however, I explore these mat-
ters in some mechanistic detail by analyzing a trial of the bispecific T cell
engager AFM11, in which a fatal toxicity occurred. To this end, I develop a
Bayesian dose-response model for a single ordinal toxicity. By construct-
ing this model’s priors to align with the AFM11 trial as designed and con-
ducted, I demonstrate the incompatibility of that design with any reason-
able expectation of safety. Indeed, the model readily yields prospective
estimates of toxic response probabilities that suggest the fatality in this
trial could have been foreseen as likely.
dose-finding studies | dose individualization | oncology | trial safety | precision
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Introduction
In October 2018, German biopharmaceutical firm Affimed N.V. an-
nounced a clinical hold on two phase 1 trials of its bispecific T cell
engager, AFM11, after 1 fatal and 2 life-threatening neurological
toxicities occurred in the highest-dose cohorts of these trials [Af-
fimed, 2018]. Six months later, Affimed announced the termination
of AFM11 development [Affimed, 2019].
The occurrence of such toxicities in a dose-escalation trial
exemplifies the precautionary coherence (PC) principle [Norris,
2017b, 2019, 2020]. The PC principle is itself a straightforward
consequence of inter-individual heterogeneity in pharmacokinet-
ics and pharmacodynamics (PKPD). Interestingly, Affimed seems
to have undertaken the clinical development of AFM11 with at
least some appreciation for the likelihood of such heterogeneity,
and for the consequent relevance of dose titration. A Decem-
ber 2015 press release [Affimed, 2015] states AFM11 “is tunable
by dosing adjustment when required.” And indeed an acknowl-
edgement of PKPD heterogeneity seems to have informed both
AFM11 trials. The first trial, NCT02106091, was formally titled,
“A Pharmacodynamically-guided, Dose-escalation, Phase I Study.”
The second trial, NCT02848911 employed step-up dosing within
each dose cohort—an accomodation that virtually acknowledges
the PC principle.
AFM11 toxic dose-response
The former trial, in CD-19 positive B-cell non-Hodgkin lymphoma
(NHL), has to my knowledge not been reported at a scientific meet-
ing or in the literature. But the latter trial, in adults with precursor
B-cell acute lymphoblastic leukemia (B-ALL), was presented at the
ASH 2018 Annual Meeting [Salogub et al., 2018] in sufficient detail
to reveal its design, dose levels, and the toxic responses for the 17
patients enrolled.
Table 1. Doses received and concomitant toxic responses for the 17 pa-
tients in AFM11 trial NCT02848911, abstracted from Salogub et al., [2018].
The step-up dosing in this trial enables abstraction of both a non-toxic
dose and a maximum dose for each patient. (For the 11 patients who ex-
perienced no toxicity at the higher dose, these doses are identical.)
Patient Non-toxic dose
(ng/kg/week)
Highest dose
(ng/kg/week)
CTCAE Grade
at highest dose
Cohort 1
1 0.7 2 2
2 2 2 0
Cohort 2
3 6 6 0
Cohort 3
4 7 20 2
5 20 20 0
6 20 20 0
Cohort 4
7 60 60 0
8 20 60 1
9 60 60 0
Cohort 5
10 180 180 0
11 180 180 0
12 60 180 3
13 180 180 0
14 180 180 0
Cohort 6
15 400 400 0
16 60 130 3
17 0 130 5
These doses and toxicities are abstracted in Table 1. The first 2
cohorts were abbreviated by an initial accelerated titration [Simon
et al., 1997] that preceded the 3 + 3 stage of the study. The step-up
dosing employed in this trial, under which each cohort’s first week
of treatment was administered at 1/3 of the cohort’s target dose,
resulted in observation of some patients (1, 4, 8 and 12) both
at a low dose that caused no toxicity, and at a higher dose that
produced a toxicity of CTCAE Grade 1 or higher. Patients 16 and
17 experienced toxicities during the first week of treatment, so
these register at the Cohort 6 starting dose of 130 ng/kg weekly.
Patient 16 recovered with a dosing interruption, and “restarted
on Cohort 5 dose” [Salogub et al., 2018], which I have taken to
mean the Cohort 5 starting dose of 60 ng/kg weekly, rather than
the full target dose of 180 ng/kg.1 Patient 17 died within the first
week of treatment, and so never received a nonzero dose that was
demonstrably non-toxic. The non-toxic dose for this patient is
therefore coded as 0. The majority (11/17) of study participants
experienced no toxicity; consequently, their tabulated non-toxic
and highest doses coincide.
1This target dose would have exceeded by 38% the 130 ng/kg weekly that had caused this patient a Grade
3 toxicity after 3 days of treatment. It seems implausible that titration so far above a patient’s previously
toxic dose would have been attempted without Salogub et al. [2018] remarking on it.
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Modeling dose-response heterogeneity for an ordinal toxicity. To
represent the inter-individual heterogeneity of toxic dose-response,
we suppose that CTCAE toxicity grade Yi ∈ {0,1,2,3,4,5} in any
given patient i is a monotone, left-continuous step function yi(x) of
dose x , with the steps occurring at doses MTDgi , g ∈ {0, ..., 5}, i ∈{1, ...,N}:
MTDgi := maxx {x |yi(x)< g}. (1)
Thus, for example, MTD3i corresponds to the highest dose that
patient i could tolerate without experiencing a grade-3 toxicity.
The transition from CTCAE grades 2 to 3 is customarily identified
with ‘intolerability’, such that grade ≥ 3 toxicities are (with certain
exceptions that won’t concern us here) regarded as ‘dose-limiting’
(DLTs). Thus when g = 3 we may drop the superscript 3 to write
‘MTDi ’ in place of MTD
3
i , and refer to this simply as i’s MTD.
We suppose that MTDi is log-normally distributed in the popu-
lation:
logMTDi ∼N (µ,τ), (2)
where the traditional Bayesian parametrization in terms of preci-
sion τ≡ σ−2 has been employed.
To promote safer phase 1 trials, our models must support ex-
trapolation from the more commonly observed toxicity grades
g ∈ {1, ..., 3} to the severe and fatal toxicities (g ∈ {4, 5}) of great-
est concern for participant safety. In the present context, we will
enable this by assuming that our toxicity grading system is some-
how aligned with the underlying pharmacology in a scale-free
manner, so that (MTDgi )
5
g=1 is a geometric sequence with ratio ri:
MTDgi = r
(g−3)
i ·MTDi (3)
log ri ∼N (log r0,τr) (4)
While I feel obliged to subscript a quantity such as ri to acknowledge
formally its likely inter-individual heterogeneity, application of this
model to the small sample sizes characteristic of phase 1 trials (and
certainly to the 17-patient trial analyzed here) requires imposing
an identifying restriction τr  1. (Had AFM11’s chief toxicity not
been uniformly neurological in nature [Smith, 2018], the hope of
extrapolating from low to high toxicity grades via Eqs. (3–4) would
be much more dubious.)
Priors for this model are specified as follows, inferred where
possible from Affimed’s design of the trial:
µ∼U(2.9, 7.5) (5)p
e1/τ − 1≡ CV ∼N (0.5,τCV = 36) (6)
r0 ∼U(1, 5). (7)
The vague uniform prior on µ spans an order of magnitude (2.3
natural logs) either side of a median MTDi at e
5.2 = 180 ng/kg
weekly, the Cohort 5 target dose. The prior over τ is obtained
indirectly from a prior placed on the more intuitively accessible
coefficient of variation (CV) of MTDi . The τCV = 36 corresponds
to σ = 1/6, which places CV ≥ 1 in the 3 s.d. upper tail of the
prior. Both the economics [Norris, 2017a, 2018] and safety [Norris,
2017b] of dose-escalation trials become obviously indefensible for
CV(MTDi) ≈ 1. Thus, Affimed’s choice of a dose-escalation trial
suggests it accorded CV(MTDi) < 1 a high prior probability. The
vague uniform prior on r0 extends to the lowest conceivable limit
r0 = 1, and is centered on r0 = 3 in accordance with this trial’s
threefold separation of dose levels (2, 6, 20, 60, 180, 400) and
with the threefold jump chosen for step-up dosing.
Model implementation. The model is implemented in JAGS [Plum-
mer, 2003] version 4.3.0, as below.2
var N; # number of patients
var okdose[N]; # a tox-free dose for each pt
var aedose[N]; # a toxic dose for each pt
var mtd[N]; # MTDi's on absolute dose scale
var mu, tau; # MTDi ~ dlnorm(mu, tau)
var cv; # tau <- 1/log(cv^2+1)
var Y[N]; # Toxicity grade for patient i=1,..,N
var Z[N]; # Dummy array of zeros for no-tox obs
data {
for (i in 1:N) {
Z[i] <- 0;
}
}
model {
mu ~ dunif(2.9, 7.5);
cv ~ dnorm(0.5, 36); # sigma=1/6 => 1=mean+3sd
tau <- 1/log(cv^2+1);
r0 ~ dunif(1, 5);
for (i in 1:N) {
mtd[i] ~ dlnorm(mu, tau);
}
for (i in 1:N) {
r[i] ~ dlnorm(log(r0), 50); # so CV(r[i]) ~ 14%
Y[i] ~ dinterval(aedose[i]/mtd[i],
c(r[i]^-2, 1/r[i], 1, r[i], r[i]^2));
Z[i] ~ dinterval(okdose[i]/mtd[i], r[i]^-2);
}
}
R package runjags [Denwood, 2016] version 2.0.4-6 was used
to run JAGS with 4 chains, each sampled 2500 times with a thinning
interval of 10, following adaptation over 1000 iterations and burn-
in of 4000.
Model estimates. Table 2 summarizes the model fit, showing po-
tential scale reduction factors near unity and large effective sample
sizes for all parameters, indicative of adequate convergence and
precision.
Figures 1 and 2 exhibit separately the posterior densities of
MTDi for patients with and without observed toxicities. The com-
parison between these Figures illustrates that observed toxicities
constitute the main source of information in dose-finding trials.
Figure 3 shows the pairwise joint posterior densities of model
hyperparameters µ, CV and r0. Notably, the posterior for CV is
centered around CV ≈ 1, which we had accorded a low prior
probability. Thus, we are ‘surprised’ to discover the substantial
heterogeneity of toxic dose-response revealed by the severe toxici-
ties in this trial. Similarly, the posterior density centering r0 ≈ 1.3,
while unremarkable from the standpoint of pharmacologic intu-
ition, suggests that in retrospect the threefold dose-level jumps
in this trial would have been too large even under circumstances
where CV 1.
2By contrast with the overloaded I(,) construct familiar to users of BUGS, the dinterval distribution
in JAGS is an ‘observable function’ that specifically implements interval censoring. See sections 7.2 and
9.2.4 of the JAGS Version 4.3.0 User Manual (28 June 2017).
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Fig. 1. Posterior densities of MTDi (on log scale) for patients who experienced toxicities.
The vertical lines show the 5 doses at which the toxicities occurred. Patients 1 and 4, who
experienced grade 2 toxicity at dose levels 1 and 3, have sharp lower bounds placed thereby
on their MTDi ’s as expected. Conversely, patients 12 and 16, who experienced grade 3
toxicities (DLTs), have upper bounds placed on their MTDi ’s. The grade 1 and 5 toxicities
experienced by patients 8 and 17 impose somewhat softer bounds due to the slack created
by the unknown r0 parameter.
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Fig. 2. Posterior densities of MTDi (on log scale) for patients who did not experience
toxicities. The vertical lines show the 6 cohort target dose levels. Patients with identical data
are of course indistinguishable from the perspective of the model; the samples from such
sets of ‘equivalent’ patients have been pooled.
Table 2. Selected quantiles, mean, and diagnostics for 10,000 MCMC sam-
ples from the model of AFM11 toxic dose-response. (SSeff: effective sam-
ple size; psrf: potential scale reduction factor.)
Lower95 Median Upper95 Mean SSeff psrf
Hyperparameters
mu 4.483 5.033 5.588 5.037 6227 1.001
cv 0.869 1.069 1.292 1.072 8515 1.001
tau 0.980 1.312 1.710 1.333 8280 1.001
r0 1.168 1.328 1.539 1.336 3773 1.002
Cohort 1
mtd[1] 2.000 2.641 3.490 2.698 5334 1.001
mtd[2] 6.818 155.074 741.512 244.976 4245 1.000
Cohort 2
mtd[3] 10.616 150.651 697.634 232.181 5990 1.000
Cohort 3
mtd[4] 20.000 24.622 32.626 25.318 7635 1.001
mtd[5] 24.685 164.743 718.587 257.397 3704 1.001
mtd[6] 26.416 162.084 712.577 246.507 4612 1.000
Cohort 4
mtd[7] 68.506 229.548 817.905 320.609 4064 1.001
mtd[8] 64.879 102.858 161.341 108.212 4444 1.001
mtd[9] 61.216 228.808 786.405 311.936 5078 1.000
Cohort 5
mtd[10] 183.516 463.337 1229.780 567.250 5316 1.001
mtd[11] 190.979 460.132 1237.230 566.082 5256 1.001
mtd[12] 134.969 159.790 179.996 158.797 10000 1.000
mtd[13] 196.548 462.334 1267.920 570.773 4241 1.001
mtd[14] 183.836 460.362 1237.710 567.768 4652 1.002
Cohort 6
mtd[15] 419.005 855.336 1938.600 988.780 5211 1.001
mtd[16] 106.057 119.836 129.999 119.013 10165 1.001
mtd[17] 11.938 50.237 95.173 52.473 9315 1.000
Discussion
Given the sparse data in this small dose-escalation study, my analy-
sis necessarily makes strong assumptions. Possibly the most con-
sequential of these has been to ignore exposure time. It seems
likely that MTDi , far from being constant for each individual, is
in fact a stochastic process, MTDi(t). Treating it here as constant
thus ignores time-to-event considerations (cf. Cheung and Chap-
pell [2000]) which may have been important in this trial. Was the
step-up dosing in this trial conceived as ‘conditioning’ patients as
with ‘ramp-up’ dosing of venetoclax to avoid tumor lysis syndrome
[Roberts et al., 2016]? If so, then abstracting away time overlooks
what may be the crucial pharmacologic point in AFM11 dosing.
Comparison with Bekele & Thall [2004]. Formally, Eqs. (1–4) invite
comparison with the ordinal probit model of Bekele and Thall
[2004], in which a latent Z variable acts like our MTDi to determine
toxicities through a relation analogous to Eq. (1):3
Y = yk if γk ≤ Z < γk+1, k ∈ {0, 1, ...,C}. (8)
Unlike our MTDi , however, the latent Z remains for Bekele and
Thall [2004] a unitless abstraction, bereft of a realistic pharma-
cologic interpretation. Similarly, they motivate their log-scaling
of dose as a technical maneuver “[t]o improve numerical stabil-
ity,” whereas here I appeal to a prior implicit in the geometrical
sequence of pre-specified AFM11 dose levels.
3Here, and throughout this comparison, I drop the extra j subscript which Bekele and Thall [2004] intro-
duced to index multiple toxicities.
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Fig. 3. Pairwise joint posterior distributions for model hyperparameters.
The (γk)Ck=0 of Bekele and Thall [2004] are likewise analogous
to our (MTDgi )
5
g=0. Because Bekele & Thall enjoyed access to sub-
stantial quantities of pseudodata via intensive prior elicitation,
they placed only vague priors on their γk ’s and did not require an
identifying restriction such as Eq. (3).
Comparison with Van Meter et al. [2012]. While the formal devel-
opments in Van Meter et al. [2012] do not present close analogues
with Eqs. (1–4), the authors’ efforts to ground their modeling in
pharmacologic realism warrant discussion. The ‘CR-CRM’ model
developed by these authors employs a continuation ratio (CR)
model, which they introduce in conjunction with an appeal to
pharmacologically realistic intuitions about toxicity:
“[T]he CR model allows for comparisons between individ-
uals in a specific toxicity category versus all individuals
that experienced a more severe toxicity grade. The CR
model also distinguishes between subjects who reached
a certain toxicity grade but did not advance to a more
severe toxicity and assumes that individuals must ‘pass
through’ the ordinal toxicities to advance to the next
highest category. In any clinical trial setting, this assump-
tion is reasonable given that we assume a patient who
experiences a grade 3 severe toxicity first presented with
symptoms resembling less severe grade 1 or 2 toxicities.”
It is remarkable to find within the statistical dose-finding lit-
erature this type of inchoate realism, alluding to patients as non-
exchangeable individuals.
The CR model stipulates that, for a toxicity grading system with
k+1 ordinal grades {0, 1, ..., k}, the population distribution of toxic
responses is such that [Van Meter et al., 2012, p.304]:
logit[Pr(Y = j|Y ≥ j, dose = x)] = α+θ j+λx; j = 0, ..., k−1, (9)
where it is understood that θ0 = 0. Under the widely adopted
CTCAE toxicity grading system, for example, we have k = 5 and
the CR model has 6 parameters: {α,θ1,θ2,θ3,θ4,γ}.
The term ‘continuation ratio’ applies here because the left-hand
side of Eq. (9) admits interpretation as the log odds for an individual
who has reached a grade- j toxicity not continuing to a higher grade.
The CR models arise in psychometrics, where they form one class
of polytomous item response theory (IRT) models Hemker et al.
[2001]. The natural toxicologic analogy would be that physiology
presents a sequence of biochemical barriers to toxicity not unlike
the difficulties presented by a sequentially scored test item. The
grade of toxicity produced by a toxin is then determined by how far
it penetrates through these sequential barriers, much as the item
score achieved by a test-taker depends on how far he advances
through the stages of item difficulty. Whereas psychometrics readily
posits latent variables with realistic interpretations, however, the
statistical literature on dose finding has thus far proven impervious
to such thinking [Norris, 2020]. Further development of the CR-
CRM model in terms of latent quantities such as MTDi may well
serve to bridge that literature into the modern era of precision
medicine, with its expectations of individualized dosing.
Anticipating and averting the fatal toxicity of patient 17. Citing
“the ethical need to control the probability of overdosing” in dose-
escalation trials, Babb et al. [1998] developed the escalation with
overdose control (EWOC) criterion. Under this scheme, each en-
rolling patient’s dose is chosen so as to limit the probability of
an ‘overdose’, defined as exceeding some population quantile of
the MTDi distribution.
4 In the same spirit, we may ask what the
probabilities of each grade of toxicity would have been in Cohort 6,
conditional on all observations up through Cohort 5. Technically,
this can be accomplished by dropping Cohort 6 patients 15–17
from the data set, and replacing them with 2 hypothetical patients:
one (at index i = 15∗) starting the 130 ng/kg weekly dose, and the
second (at i = 16∗) stepping up to the full 400 ng/kg weekly, after
no toxicity at the starting dose. The unobserved nodes Y[15] and
Y[16] may then be sampled to predict the distribution of toxicities
in Cohort 6.5 Table 3 shows the hyperparameter estimates without
the Cohort 6 data remain reasonably close to those in Table 2.
Table 3. Selected quantiles, mean, and diagnostics for 10,000 MCMC hy-
perparameter samples from the model estimated against data from Co-
horts 1–5. Also sampled is MTD15∗ , by construction a random sample
from the posterior distribution of population MTDi immediately before the
first enrollment in Cohort 6.
Lower95 Median Upper95 Mean SSeff psrf
Hyperparameters
mu 4.509 5.167 5.808 5.176 3272 1.0007
cv 0.847 1.056 1.269 1.058 7508 1.0000
tau 0.992 1.335 1.752 1.360 7854 1.0000
r0 1.166 1.407 1.704 1.424 1972 1.0006
Population MTDi
mtd[15*] 10.278 173.204 817.957 272.691 4295 1.0002
Figure 4 exhibits the toxicity distributions for these hypothetical
patients. The model is seen to predict that each patient enrolling
in Cohort 6 risks a fatal toxicity even at the starting dose, with
probability exceeding 16%. More realistic prior elicitation and
modeling of AFM11 toxic dose-response thus might have informed
safer design and conduct of this trial.
4Working as they did entirely within the one-size-fits-all dose-finding framework, Babb et al. [1998] did not
explicitly recognize this quantile as such, but referred to it simply as "the MTD."
5See section 3.2, page 15 of the JAGS Version 4.3.0 User Manual.
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Fig. 4. Probabilities of Cohort 6 toxicities by CTCAE Grade, as would have been predicted
by the model prior to enrollment. Distributions are given separately for the Cohort 6 starting
dose, and for step-up to the full target dose conditional on no toxicity with the starting dose.
(With 10,000 MCMC samples, the Monte Carlo standard errors are too small to display.)
Conclusion
I have developed here a Bayesian model of heterogeneous dose-
response for an ordinal toxicity, and used it to examine retrospec-
tively the safety of dose-finding trial that was halted for a fatal
toxicity. The model supports an interim analysis suggesting the
fatalilty in this trial could have been anticipated and averted. With-
out loss of generality, this mode of analysis may be applied at every
dosing decision in a dose-finding trial. Thus, it forms the basis
for designing and implementing safer dose-finding designs in the
future. With access to sufficient pseudodata from prior elicitation,
some of the strong identifying restrictions employed here may (and
should) be relaxed. Being grounded in realistic pharmacologic
intuitions, and explicitly recognizing patients as non-exchangeable
individuals, this model may prove well suited to such prior elicita-
tion with clinicians.
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